Floatz logo

Omalizumab

Chronic Sinusitis

University of California, San Franciscomonoclonal_antibodyPhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Chronic Sinusitis cohort.

Asset / SponsorPhaseRating
Cipralex
University of Washington
Phase 4BB
METHOXIFLURANE
St. Paul's Hospital, Canada
Phase 1/2CCC
S-Ketamine
The Second People's Hospital of Huai'an
Phase 1/2CC
LAVENDER OIL
Cedars-Sinai Medical Center
N/AD
Ivacaftor
University of California, Los Angeles
D

View all 9 →

Same molecule, other indications

Omalizumab is also rated in:

allergic asthmaDormant
BBB
Indicative ·
76 / 100
View asset →
asthmaDormant
BB
Indicative ·
68 / 100
View asset →
allergic bronchopulmonary aspergillosisDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →